

HVPG RESPONSE TO CHRONIC PROPRANOLOL

Year	First author	Type	prophylaxis`	n	% R	definition R	intervention NR	HVPG	Bleeding RESP NR	fu
1990	Groszmann	RCT	propranolol vs placebo	102	31%	<12 mmHg	none	0,3,12,24 mo	0% 5%	24 mo
2000	Escorsell	series	propranolol max tolerated	55	38%	↓>20%	none	0 and 3-5 mo	0% 31%	24 mo
2000	Merkel	series	propranolol max tolerated	49	61%	<12 or ↓>20%	ISMN add-on	0 and 1-3 mo	7% 41%	36 mo
2002	Bureau	series	propranolol 160 mg eod	20	70%	<12 or ↓>20%	ISMN add-on; VBL	na	10% 64%	28 mo
2003	Aracil	series	nadololol dose na	72	31%	↓>20%	none	0 and 1-3 mo	na na	37 mo
2006	Turnes	series	propranolol±ISMN	71	35%	<12 or ↓>20%	none	0 and 4 mo	8% 30%	8 y
2007	Albillos (1-4,6)	meta-analysis		353	49%	<12 or ↓>20%			6% 32%	
2009	Sharma	series	propranolol dose na	56	38%	<12 or ↓>20%	ISMN add-on	0 and 1 mo	4% 22%	24 mo
2009	Villanueva	series	nadolol max tolerated	73	64%	<12 or ↓>10%	none	0 and 1-3 mo	2% 46%	25 mo
2010	de-Madaria	series	propranolol max tolerated	15	40%	<12 or ↓>20%	none	0 and 3 mo	0/6 0/9	14 mo
2010	Merkel	series	nadolol max tolerated	24	65%	<12 or ↓>20%	ISMN add-on; VBL	0,1,18,54 mo	0% 31%	48 mo

HVPG RESPONSE TO ACUTE PROPRANOLOL

Year	First author	Type	prophylaxis`	n	% R	definition R	intervention NR	HVPG	Bleeding RESP NR	fu
2000	De Binay	series	propranolol 80 mg orally	18	83%	↓>20%	ISMN or spironolacton	single	na na	9-38m
2003	Aracil	series	propranolol 0.15 mg/kg iv.	55	38%	↓>20%	none	single	na na	37 mo
2009	La Mura	series	propranolol 0.15 mg/kg iv.	78	69%	<12 or ↓>20%	none	single	12% 23%	24 mo
2009	Villanueva	series	propranolol bolus+ 0.2 mg/h iv.	105	71%	<12 or ↓>10%	none	single	4% 43%	25 mo
2010	de-Madaria	series	propranolol 0.15 mg/kg iv.	20	25%	<12 or ↓>20%	none	single	0/5 3/15	14 mo

HVPG, hepatic venous pressure gradient; ISMN, isosorbide-5-mononitrate; R, response to HVPG ; %R, percentage HVPG responders; NR, nonresponder to HVPG; VBL, endoscopic variceal band ligation; definition R, definition of HVPG response; fu, follow-up; na, not available.